Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice.
The histone demethylase JMJD1C is overexpressed in patients with myeloproliferative neoplasms (MPNs) and has been implicated in leukemic stem cell function of MLL-AF9 and HOXA9-driven leukemia. In the emerging field of histone demethylase inhibitors, JMJD1C therefore became a potential target. Deple...
Main Authors: | Hans F Staehle, Johannes Heinemann, Albert Gruender, Anne M Omlor, Heike Luise Pahl, Jonas Samuel Jutzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228362 |
Similar Items
-
The Cross Marks the Spot: The Emerging Role of JmjC Domain-Containing Proteins in Myeloid Malignancies
by: Hans Felix Staehle, et al.
Published: (2021-12-01) -
JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01) -
JAK2 V617F ALLELE BURDEN IN CHRONIC MYELOPROLIFERATIVE DISEASES
by: Matevž Škerget, et al.
Published: (2008-04-01) -
A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01) -
Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
by: Soumaya Chadi, et al.
Published: (2021-04-01)